Congratulations on a very good FY26 performance. Would it be possible for the management to provide the capacity utilization across the 3 units at the moment?
Okay. And in the initial comments, you talked about the longer capital deployment cycle now. Can you elaborate a little more on this? So what are we thinking in terms of capex and utilization of the cash that we have generated in FY26?
Hi. Thanks for the opportunity and congratulations on a good set of numbers. In the first two products that you have mentioned, you have shipped, are we currently an exclusive supplier to the innovators?
Understood. My second question is on the third molecule that you mentioned. So, can you provide more information on this product, whether it is a high-volume product and would Neuland have an opportunity to become an exclusive supplier in this product?
Hi, thanks for the opportunity. Now my question is on the India business. We have done MR additions, we have done a few launches and we also have forayed in new therapies. So, over two to three-year period, how do you see the India business shaping up?
And the new therapies that we have entered, when do you think that those therapies could be contributing substantially, let's say, meaningfully? What could be the, let's say, three-year, five- year period where we think this can add meaningful value?
Just 2 questions. Question number 1 is on the domestic side. We had discussed some time back about the gaps in the portfolio. So where we are in the -- or in some other therapies. That is question number one. And question number 2 will be, if you can comme nt on the emerging market MR productivity?
Yes, sure. So there was a discussion that there are portfolio gaps in our therapies?
I have 3 questions. First question is on the Institutional business. FY'24 was a good year. So can you comment on this performance and the outlook of this business?
Understood. And going by FY'24 EBITDA margin performance, how should we see the U.S. margins in FY'24? And if you can comment, which are the most profitable segments in terms of margins for you currently?